4.7 Review

Adiposopathy Is Sick Fat a Cardiovascular Disease?

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 57, 期 25, 页码 2461-2473

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2011.02.038

关键词

adiposity; adiposopathy; cardiovascular disease; metabolic syndrome; obesity; obesity paradox

资金

  1. Abbott
  2. Aegerion
  3. Akros
  4. Amarin
  5. Amgen
  6. Amylin
  7. Alteon
  8. Arena
  9. Arete
  10. AstraZeneca
  11. Aventis
  12. Bayer
  13. Boehringer
  14. Bristol-Myers Squibb
  15. California Raisin Board
  16. Cargill
  17. Ciba Geigy
  18. Daiichi Sankyo
  19. Eli Lilly
  20. Esperion
  21. Essentialis
  22. Forest
  23. Fujisawa
  24. GelTex
  25. Genentech
  26. Gilead
  27. GlaxoSmithKline
  28. Hoechst Roussel
  29. Hoffman LaRoche
  30. Home Access
  31. InterMune
  32. Intekrin
  33. Ironwood Pharmaceuticals
  34. ISIS
  35. Johnson Johnson
  36. KOS
  37. Kowa
  38. Kyorin
  39. Lederle
  40. Marion Merrell Dow
  41. Merck
  42. Merck Schering-Plough
  43. Metabolex
  44. Miles
  45. Microbia
  46. Neuromed
  47. Nicox
  48. Novartis
  49. NovoNordisk
  50. Obecure
  51. Omthera
  52. Orexigen
  53. Parke Davis
  54. Pfizer
  55. Pliva
  56. Pozen
  57. Purdue
  58. Reliant
  59. Roche
  60. Rorer
  61. Regeneron
  62. Sandoz
  63. Sanofi
  64. Sciele
  65. Searle
  66. Shionogi
  67. Schering-Plough
  68. SmithKline Beacham
  69. Stratum Nutrition
  70. Surface Logix
  71. Takeda
  72. TAP
  73. Trygg
  74. TWI Bio
  75. UpJohn
  76. Upsher Smith
  77. Warner Lambert
  78. Vivus
  79. Wyeth-Ayerst
  80. Zeomedex

向作者/读者索取更多资源

Being overweight or obese is a worldwide epidemic. Adiposity can cause fat mass-related cardiovascular disease (CVD). Adiposity may also cause adipocyte and adipose tissue anatomic and functional abnormalities, termed adiposopathy (adipose-opathy) or sick fat, that result in endocrine and immune derangements. Adiposopathy may directly contribute to CVD through pericardiac and perivascular effects on the myocardium and blood vessels. Adiposopathy may also indirectly contribute to CVD through promoting or worsening major CVD risk factors such as type 2 diabetes mellitus, high blood pressure, and dyslipidemia. Despite CVD being the most common cause of mortality among overweight individuals, the pathophysiologic relationship between adiposity and CVD is often thought mysterious, as evidenced by obesity paradoxes. Underlying this uncertainty are suggestions that excessive body fat does not always increase the risk of CVD and, in some cases, may actually decrease such risks. These paradoxical findings are made less paradoxical when the pathogenic potential of excessive body fat is assessed based on adipose tissue dysfunction rather than simply on increased fat mass alone. This introductory review 1) provides a brief historical perspective of the pathogenic potential of adipose tissue; 2) describes the relationships between adipose tissue (histology, embryology, and adipogenesis) and cardiovascular medicine; 3) outlines the anatomic, functional, endocrine, and immune manifestations of adiposopathy; and 4) describes the importance of cross talk and/or interactions of adipose tissue with other body tissues. Finally, this review describes how sick fat helps account for various clinical obesity/cardiovascular paradoxes, supporting adiposopathy as a cardiovascular disease. (J Am Coll Cardiol 2011; 57: 2461-73) (C) 2011 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据